Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

Recent developments in health highlight key agreements between countries, drug approvals, corporate revenue growth, and ...

Bionxt Solutions is preparing for a pilot clinical trial to test its sublingual formulation of cladribine to treat multiple ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

The global CHPTAC market is valued at USD 264 million in 2025 and is expected to reach USD 430 million by 2035. CHPTAC’s primary application lies in water treatment and paper manufacturing. The market ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck (NYSE:MRK) operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal ...